Human secreted tau increases amyloid-beta production

Neurobiology of Aging

Volumn 36, Issue 2, 2015, Pages 693-709

  Bright, Jessica ^a   Hussain, Sami ^a   Dang, Vu ^a   Wright, Sarah ^a   Cooper, Bonnie ^a   Byun, Tony ^a   Ramos, Carla ^a   Singh, Andrew ^a   Parry, Graham ^a   Stagliano, Nancy ^a   Griswold Prenner, Irene ^a  

^a IPierian ^*  (United States)

Author keywords

Alzheimer's disease; Amyloid beta (A ); ETau; Extracellular tau; Feed forward mechanism; Neuronal hyperactivity; SAPP ; Secreted tau

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD LEVEL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN SECRETION; SEQUENCE ANALYSIS; ANIMAL; BRAIN CORTEX; CELL CULTURE; CHEMISTRY; CYTOLOGY; ISOLATION AND PURIFICATION; METABOLISM; NERVE CELL; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELLS, CULTURED; CEREBRAL CORTEX; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; MICE, TRANSGENIC; NEURONS; TAU PROTEINS;

EID: 84922785301     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.09.007     Document Type: Article

References (41)

1. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 1995, 16:271-278.
2. Braak H., Del T.K. Alzheimer's disease: intraneuronal alterations precede insoluble amyloid-beta formation. Neurobiol. Aging 2004, 25:713-718.
3. Braak H., Zetterberg H., Del T.K., Blennow K. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-beta changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol. 2013, 126:631-641.
4. Burkhardt M.F., Martinez F.J., Wright S., Ramos C., Volfson D., Mason M., Garnes J., Dang V., Lievers J., Shoukat-Mumtaz U., Martinez R., Gai H., Blake R., Vaisberg E., Grskovic M., Johnson C., Irion S., Bright J., Cooper B., Nguyen L., Griswold-Prenner I., Javaherian A. Acellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol. Cell Neurosci. 2013, 56:355-364.
5. Chai X., Dage J.L., Citron M. Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol. Dis. 2012, 48:356-366.
6. Chambers S.M., Fasano C.A., Papapetrou E.P., Tomishima M., Sadelain M., Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 2009, 27:275-280.
7. Cirrito J.R., Kang J.E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., Bu G., Mennerick S., Holtzman D.M. Endocytosis is required for synaptic activity-dependent release of amyloid-beta invivo. Neuron 2008, 58:42-51.
8. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-beta levels invivo. Neuron 2005, 48:913-922.
9. Colombo A., Wang H., Kuhn P.H., Page R., Kremmer E., Dempsey P.J., Crawford H.C., Lichtenthaler S.F. Constitutive α- and β-secretase cleavages of the amyloid precursor protein are partially coupled in neurons, but not in frequently used cell lines. Neurobiol. Dis. 2012, 49:137-147.
10. de Calignon A., Polydoro M., Suarez-Calvet M., William C., Adamowicz D.H., Kopeikina K.J., Pitstick R., Sahara N., Ashe K.H., Carlson G.A., Spires-Jones T.L., Hyman B.T. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012, 73:685-697.
11. DeVos S.L., Goncharoff D.K., Chen G., Kebodeaux C.S., Yamada K., Stewart F.R., Schuler D.R., Maloney S.E., Wozniak D.F., Rigo F., Bennett C.F., Cirrito J.R., Holtzman D.M., Miller T.M. Antisense reduction of tau in adult mice protects against seizures. J.Neurosci. 2013, 33:12887-12897.
12. Dimos J.T., Rodolfa K.T., Niakan K.K., Weisenthal L.M., Mitsumoto H., Chung W., Croft G.F., Saphier G., Leibel R., Goland R., Wichterle H., Henderson C.E., Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321:1218-1221.
13. Dujardin S., Lecolle K., Caillierez R., Begard S., Zommer N., Lachaud C., Carrier S., Dufour N., Auregan G., Winderickx J., Hantraye P., Deglon N., Colin M., Buee L. Neuron-to-neuron wild-type tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol. Commun. 2014, 2:14.
14. Gotz J., Chen F., van D.J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
15. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
16. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
17. Holth J.K., Bomben V.C., Reed J.G., Inoue T., Younkin L., Younkin S.G., Pautler R.G., Botas J., Noebels J.L. Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J.Neurosci. 2013, 33:1651-1659.
18. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van E.J., Wolfing H., Chieng B.C., Christie M.J., Napier I.A., Eckert A., Staufenbiel M., Hardeman E., Gotz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
19. Jeganathan S., von B.M., Brutlach H., Steinhoff H.J., Mandelkow E. Global hairpin folding of tau in solution. Biochemistry 2006, 45:2283-2293.
20. Jicha G.A., Lane E., Vincent I., Otvos L., Hoffmann R., Davies P. Aconformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J.Neurochem. 1997, 69:2087-2095.
21. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., Malinow R. APP processing and synaptic function. Neuron 2003, 37:925-937.
22. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
23. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van S.M., Gwinn-Hardy K., Paul M.M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 2000, 25:402-405.
24. Liu L., Drouet V., Wu J.W., Witter M.P., Small S.A., Clelland C., Duff K. Trans-synaptic spread of tau pathology invivo. PLoS One 2012, 7:e31302.
25. McConlogue L., Buttini M., Anderson J.P., Brigham E.F., Chen K.S., Freedman S.B., Games D., Johnson-Wood K., Lee M., Zeller M., Liu W., Motter R., Sinha S. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J.Biol. Chem. 2007, 282:26326-26334.
26. Meredith J.E., Sankaranarayanan S., Guss V., Lanzetti A.J., Berisha F., Neely R.J., Slemmon J.R., Portelius E., Zetterberg H., Blennow K., Soares H., Ahlijanian M., Albright C.F. Characterization of novel CSF tau and ptau biomarkers for Alzheimer's disease. PLoS One 2013, 8:e76523.
27. Pooler A.M., Phillips E.C., Lau D.H., Noble W., Hanger D.P. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013, 14:389-394.
28. Rapoport M., Dawson H.N., Binder L.I., Vitek M.P., Ferreira A. Tau is essential to beta -amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6364-6369.
29. Ribe E.M., Perez M., Puig B., Gich I., Lim F., Cuadrado M., Sesma T., Catena S., Sanchez B., Nieto M., Gomez-Ramos P., Moran M.A., Cabodevilla F., Samaranch L., Ortiz L., Perez A., Ferrer I., Avila J., Gomez-Isla T. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol. Dis. 2005, 20:814-822.
30. Roberson E.D., Halabisky B., Yoo J.W., Yao J., Chin J., Yan F., Wu T., Hamto P., Devidze N., Yu G.Q., Palop J.J., Noebels J.L., Mucke L. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J.Neurosci. 2011, 31:700-711.
31. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
32. Schonheit B., Zarski R., Ohm T.G. Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol. Aging 2004, 25:697-711.
33. Schweers O., Schonbrunn-Hanebeck E., Marx A., Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J.Biol. Chem. 1994, 269:24290-24297.
34. Shipton O.A., Leitz J.R., Dworzak J., Acton C.E., Tunbridge E.M., Denk F., Dawson H.N., Vitek M.P., Wade-Martins R., Paulsen O., Vargas-Caballero M. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J.Neurosci. 2011, 31:1688-1692.
35. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
36. Terwel D., Lasrado R., Snauwaert J., Vandeweert E., Van H.C., Borghgraef P., Van L.F. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J.Biol. Chem. 2005, 280:3963-3973.
37. Verges D.K., Restivo J.L., Goebel W.D., Holtzman D.M., Cirrito J.R. Opposing synaptic regulation of amyloid-beta metabolism by NMDA receptors invivo. J.Neurosci. 2011, 31:11328-11337.
38. Vossel K.A., Zhang K., Brodbeck J., Daub A.C., Sharma P., Finkbeiner S., Cui B., Mucke L. Tau reduction prevents A{beta}-induced defects in axonal transport. Science 2010, 330:198.
39. Wright S., Parham C., Lee B., Clarke D., Auckland L., Johnston J., Lawrence A.L., Dickeson S.K., Santoro S.A., Griswold-Prenner I., Bix G. Perlecan domain V inhibits alpha2 integrin-mediated amyloid-beta neurotoxicity. Neurobiol. Aging 2012, 33:1379-1388.
40. Yamada K., Cirrito J.R., Stewart F.R., Jiang H., Finn M.B., Holmes B.B., Binder L.I., Mandelkow E.M., Diamond M.I., Lee V.M., Holtzman D.M. Invivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J.Neurosci. 2011, 31:13110-13117.
41. Yamada K., Holth J.K., Liao F., Stewart F.R., Mahan T.E., Jiang H., Cirrito J.R., Patel T.K., Hochgrafe K., Mandelkow E.M., Holtzman D.M. Neuronal activity regulates extracellular tau invivo. J.Exp. Med. 2014, 211:387-393.